Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

stant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") ... today announces that application has been sought for 530,000 new ... admitted to trading on AIM. The new Ordinary Shares are ... Philip Haworth, former Chief Executive Officer of Silence. ...
... WEST LAFAYETTE, Ind. ╨ Engineers have discovered details about ... new applications in manufacturing, diagnostics and other research., ... create features and surface textures in metals, ceramics and other ... biosensors. The lasers pulse at durations of 100 femtoseconds, or ...
... CAMBRIDGE, Mass., Dec. 19, 2011 Access Industries ... a new life sciences venture investment initiative to ... team,s experience in startup creation, technology commercialization and ... and also create de-novo spinoffs around potential high-impact ...
Cached Biology Technology:Silence Therapeutics Additional Listing 2Silence Therapeutics Additional Listing 3Research could improve laser-manufacturing technique 2Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities 2Access BridgeGap Ventures to Focus on Early-Stage Therapeutic Opportunities 3
(Date:4/15/2014)... of Arts and Sciences (KNAW) has announced the names ... prestigious Heineken Prizes (one million US dollars prize money ... their great merits to science. , This year marks ... to the Austrian-American chemist Erwin Chargaff in 1964. , ... to the following laureates: , Christopher M. ...
(Date:4/15/2014)... soon could be powering the forklifts used in warehouses ... faster refueling times than ever before, courtesy of a ... (HHC). , The goal of the project is to ... at low pressure four to five times faster than ... a competitive advantage over batteries for a big slice ...
(Date:4/14/2014)... to unravel the molecular changes that underlie one of ... When the bacterium Yersinia pestis enters the lungs, it ... fatal if untreated. The way in which Y. ... in a matter of days has largely confounded scientists, ... the presence of a protein called the plasminogen activator ...
Breaking Biology News(10 mins):Five scientists awarded prestigious Heineken Prizes 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 2Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 3Low-cost, hydrogen-powered forklifts with rapid refueling, zero emissions coming soon 4Plague alters cell death to kill host 2
... Iceland,s Eyjafjallajoekull volcano have produced a 1600 km-wide ash ... and then south, is clearly visible in stark contrast ... May. The volcano began emitting steam and ash ... month. Renewed activity earlier this week caused some flights ...
... Assistant Professor Carla Finkielstein has been presented with a ... by the American Association for Cancer Research (AACR), is ... researchers and increase the recognition of minorities involved in ... in the Department of Biological Sciences in the College ...
... a leading scientist at the Office of Naval Research, discussed ... and wastewater during National Public Radio,s recent "Science Friday" segment. ... of the microbial fuel cell to power different types of ... program officer for ONR,s Naval Biosciences and Biocentric Technology Program. ...
Cached Biology News:Biologist Carla Finkielstein receives Minority Scholar Award 2ONR scientist generates 'mud power' for NPR radio audience 2
... is the universal bioinformatics software that has ... The unique modular design of BioNumerics allows ... any type of data employed for the ... DNA fingerprints, 2-D protein gels, HPLC, VNTR, ...
Request Info...
Cultrex 3D Culture Matrix Rat Collagen I....
Cultrex 3D Culture Matrix BME....
Biology Products: